RPRX
Royalty Pharma plc
NASDAQ · USHealthcareBiotechnology
$58.48+0.51%
Price as of Jul 20, 2026
RPRX ownership
Royalty Pharma plc ownership & insider activity
Latest available institutional positioning and SEC Form 4 insider transactions, coalesced at the company entity level when listings share coverage.
Insider Activity
Sentiment
0/100
Buys (3m)
0
Sells (3m)
10
Net (3m)
-$16.0M
Insider trades by month Buys Sells
Feb
Mar
Apr
May
Jun
Jul
Context3-month price +18%Institutions accumulating (13F)
| Date | Insider | Type | Shares | Price |
|---|---|---|---|---|
| Jul 2, 2026 | Urist Marshallofficer: EVP, Research & Investments | Sell | 9,099 | $55.88 |
| Jun 30, 2026 | Bassler Bonnie Ldirector | Grant | 689 | $54.40 |
| Jun 25, 2026 | Urist Marshallofficer: EVP, Research & Investments | Sell | 9,098 | $55.18 |
| Jun 25, 2026 | Hite Christopherofficer: EVP & Chairman, Partnering | Sell | 117,592 | $54.47 |
| Jun 25, 2026 | Hite Christopherofficer: EVP & Chairman, Partnering | Sell | 32,408 | $54.11 |
| Jun 8, 2026 | WEATHERMAN ELIZABETH Hdirector | Grant | 4,545 | — |
| Jun 8, 2026 | Coric Vladdirector | Grant | 4,545 | — |
| Jun 8, 2026 | Engelbert Catherine M.director | Grant | 4,545 | — |
| Jun 8, 2026 | LOVE TED Wdirector | Grant | 4,545 | — |
| Jun 8, 2026 | Bassler Bonnie Ldirector | Grant | 4,545 | — |
| Jun 8, 2026 | Norden Gregorydirector | Grant | 4,545 | — |
| Jun 8, 2026 | HODGSON DAVID Cdirector | Grant | 4,545 | — |
| Jun 8, 2026 | Ho Caroledirector | Grant | 4,545 | — |
| May 28, 2026 | Coyne Terrance P.officer: EVP & CFO | Sell | 64,399 | $53.98 |
| May 21, 2026 | Urist Marshallofficer: EVP, Research & Investments | Sell | 13,684 | $52.75 |
| May 15, 2026 | Norden Gregorydirector | Sell | 3,045 | $53.00 |
| May 15, 2026 | Urist Marshallofficer: EVP, Research & Investments | Sell | 13,684 | $53.06 |
| May 8, 2026 | Hite Christopherofficer: EVP & Vice Chairman | Grant | 24,263 | — |
| May 8, 2026 | Urist Marshallofficer: EVP, Research & Investments | Grant | 18,197 | — |
| May 8, 2026 | Legorreta Pablo G.director, officer: CEO, Chairman of the Board | Grant | 143,821 | — |
| May 8, 2026 | Coyne Terrance P.officer: EVP & CFO | Grant | 24,263 | — |
| Apr 30, 2026 | Coyne Terrance P.officer: EVP & CFO | Sell | 1,875 | $49.78 |
| Apr 30, 2026 | Coyne Terrance P.officer: EVP & CFO | Sell | 32,916 | $49.78 |
| Apr 2, 2026 | Coyne Terrance P.officer: EVP & CFO | Sell | 32,916 | $48.33 |
| Apr 2, 2026 | Coyne Terrance P.officer: EVP & CFO | Sell | 1,875 | $48.33 |
| Mar 31, 2026 | Bassler Bonnie Ldirector | Grant | 815 | $45.98 |
| Mar 25, 2026 | Coyne Terrance P.officer: EVP & CFO | Sell | 1,875 | $45.53 |
| Mar 25, 2026 | Coyne Terrance P.officer: EVP & CFO | Sell | 32,916 | $45.53 |
| Mar 4, 2026 | Coyne Terrance P.officer: EVP & CFO | Sell | 583 | $47.01 |
| Mar 4, 2026 | Coyne Terrance P.officer: EVP & CFO | Sell | 22,487 | $46.67 |
Source: RPRX SEC Form 4 filings, latest Jul 2, 2026. For informational purposes only — not investment advice.
Institutional activity (13F)
How institutions changed their RPRX positions over the last 6 months (SEC Form 13F).
Increased
482
New positions
207
Reduced
326
Sold out
112
Largest moves
| Institution | Action | Shares | Filed |
|---|---|---|---|
| MORGAN STANLEY | Increased | 55.3M | Feb 13, 2026 |
| MORGAN STANLEY | Reduced | 43.6M | May 15, 2026 |
| CAPITAL INTERNATIONAL INVESTORS | Increased | 35.0M | May 13, 2026 |
| CAPITAL INTERNATIONAL INVESTORS | Increased | 31.1M | Feb 11, 2026 |
| FMR LLC | Reduced | 26.3M | Feb 17, 2026 |
| BLACKROCK, INC. | Reduced | 26.2M | Feb 12, 2026 |
| BLACKROCK, INC. | Reduced | 25.9M | May 13, 2026 |
| FMR LLC | Reduced | 25.2M | May 15, 2026 |
| BAILLIE GIFFORD & CO | Reduced | 17.0M | Jan 23, 2026 |
| BAILLIE GIFFORD & CO | Reduced | 16.2M | May 8, 2026 |
| SWEDBANK AB | Reduced | 11.9M | Feb 9, 2026 |
| ADAGE CAPITAL PARTNERS GP, L.L.C. | Reduced | 11.7M | Feb 17, 2026 |
| SWEDBANK AB | Reduced | 11.6M | Apr 29, 2026 |
| STATE STREET CORP | Increased | 11.0M | May 15, 2026 |
| Swedbank AB | Reduced | 10.7M | Jul 15, 2026 |
Source: SEC Form 13F filings. For informational purposes only — not investment advice.